Estrogen regulation of neurotrophin expression in sympathetic neurons and vascular targets.
We hypothesize that estrogen exerts a modulatory effect on sympathetic neurons to reduce neural cardiovascular tone and that these effects are modulated by nerve growth factor (NGF), a neurotrophin that regulates sympathetic neuron survival and maintenance. We examined the effects of estrogen on NGF and tyrosine hydroxylase (TH) protein content in specific vascular targets. Ovariectomized, adult Sprague-Dawley rats were implanted with placebo or 17beta-estradiol (release rate, 0.05 mg/day). Fourteen days later, NGF levels in the superior cervical ganglia (SCG) and its targets, the heart, external carotid artery, and the extracerebral blood vessels, as well as estrogen receptor alpha (ERalpha) content levels in the heart, were determined using semi-quantitative Western blot analysis. TH levels in the SCG and extracerebral blood vessels were determined by Western blotting and immunocytochemistry, respectively. Circulating levels of 17beta-estradiol and prolactin (PRL) were quantified by RIA. Estrogen replacement significantly decreased NGF protein in the SCG and its targets, the external carotid artery, heart and extracerebral blood vessels. TH protein associated with the extracerebral blood vessels was also significantly decreased, but ERalpha levels were significantly increased in the heart following estrogen replacement. These results indicate that estrogen reduces NGF protein content in sympathetic vascular targets, which may lead to decreased sympathetic innervations to these targets, and therefore reduced sympathetic regulation. In addition, the estrogen-induced increase in ERalpha levels in the heart, a target tissue of the SCG, suggests that estrogen may sensitize the heart to further estrogen modulation, and possibly increase vasodilation of the coronary vasculature.
Kaur
Gurjinder
G
Center for Neuroscience and Behavior, Department of Zoology, Miami University, Oxford, OH 45056, USA. gkaur@nki.rfmh.org
Janik
James
J
Isaacson
Lori G
LG
Callahan
Phyllis
P
D000320:Adrenergic Fibers / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000098:blood supply; D002342:Carotid Artery, External / Q000294:innervation / Q000378:metabolism; D002536:Cerebral Arteries / Q000294:innervation / Q000378:metabolism; D015536:Down-Regulation; D004958:Estradiol / Q000502:physiology*; D047628:Estrogen Receptor alpha / Q000378:metabolism; D015914:Estrogen Replacement Therapy; D005260:Female; D006321:Heart / Q000294:innervation; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D009206:Myocardium / Q000378:metabolism; D020932:Nerve Growth Factor / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism*; D010052:Ovariectomy; D011388:Prolactin / Q000097:blood; D020033:Protein Isoforms; D051381:Rats; D017207:Rats, Sprague-Dawley; D017783:Superior Cervical Ganglion / Q000166:cytology / Q000378:metabolism*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism*; D014664:Vasodilation / Q000502:physiology
D047628:Estrogen Receptor alpha; D020033:Protein Isoforms; D004958:Estradiol; D011388:Prolactin; D020932:Nerve Growth Factor; D014446:Tyrosine 3-Monooxygenase